Laith J. Abu-Raddad i wsp. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Eng J Med 2021 online
The estimated effectiveness of the vaccine against any documented infection with the B.1.1.7 variant was 89.5% (95% confidence interval [CI], 85.9 to 92.3).
The effectiveness against any documented infection with the B.1.351 variant was 75.0% (95% CI, 70.5 to78.9).
Vaccine effectiveness against severe, critical, or fatal disease due to infection with any SARS-CoV-2 (with the B.1.1.7 and B.1.351 variants being predominant within Qatar) was very
high, at 97.4% (95% CI, 92.2 to 99.5).
Nevertheless, the reduced protection against infection with the B.1.351 variant did not seem to translate into poor protection against the most severe forms of infection (i.e., those resulting
in hospitalization or death), which was robust, at greater than 90%.
NEJM, 5 maja 2021